Active Filter(s):
Details:
The net proceeds will be used to pioneer precision immuno-oncology using company's next-generation T cell engagers, which are bispecific antibody-like molecules designed to simultaneously bind both a T cell and a tumor-specific mutant peptide.
Lead Product(s): T Cell Engagers
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Catalio Capital Management
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 20, 2024